Keywords: Neoplasms, Radiopharmaceuticals, Theranostics, 1 Fluoro 3 (2 Nitro 1 Imidazolyl) 2 Propanol F 18, Antineoplastic Agent, Cetuximab, Cetuximab Macrogol Pentetate Indium In 111, Cisplatin, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Kinase Inhibitor, Fluorodeoxyglucose F 18, Fluoroerythronitroimidazole F 18, Fluorothymidine F 18, Gemtuzumab Ozogamicin, Glycoprotein P Inhibitor, Ibritumomab Tiuxetan, Imatinib, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Methylthiosemicarbazone Cu 62, Monoclonal Antibody, Monoclonal Antibody 528 Pentetate Indium In 111, Protein Tyrosine Kinase Inhibitor, Radiopharmaceutical Agent, Scatter Factor Receptor, Sorafenib, Sunitinib, Tositumomab I 131, Trastuzumab, Tumor Antigen, Unclassified Drug, Unindexed Drug, Upenazime Tc 99m, Yttrium 86, Acute Granulocytic Leukemia, Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Growth, Cancer Theranostics, Clinical Trial, Diagnostic Accuracy, Drug Distribution, Drug Response, Drug Targeting, Drug Treatment Failure, Human, Hypoxia, Isotope Labeling, Lung Non Small Cell Cancer, Molecular Imaging, Multidrug Resistance, Nonhodgkin Lymphoma, Nonhuman, Nuclear Medicine, Positron Emission Tomography, Protein Expression, Radioimmunotherapy, Review, Sensitivity And Specificity, Single Photon Emission Computer Tomography, Animals, Diagnostic Imaging, Drug Delivery Systems, Drug Design, Forecasting, Molecular Probe Techniques, Diagnostic Imaging Trends
, Drug Delivery Systems Trends
, Isotope Labeling Methods
, Molecular Probe Techniques Trends
, Neoplasms Diagnostic Imaging Radiotherapy
, Nuclear Medicine Trends
, Radionuclide Imaging
, Radiopharmaceuticals Therapeutic Use,
Affiliations: *** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Edificio 10, Via S. Pansini 5, 80131 Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research (CNR), Naples, Italy
References: Not available.
Nuclear imaging in cancer theranostics
The combination of a diagnostic test with a therapeutic entity is termed theranostics. The diagnostic test aims at identifying patients who will likely benefit from a specific therapeutic intervention, fail to respond or eventually manifest side effects to a given drug. The appropriate selection of patients for innovative therapies would promote an enrichment of patient population that can potentiate clinical trials and, eventually, accelerate the drug development process. For these reasons, many drug companies adopted a theranostic approach as a new and promising avenue for drug development. From an historical perspective, the concepts underlying the theranostic strategy are well known in nuclear medicine and constituted the basis of many nuclear imaging procedures currently used in clinical practice. Nevertheless the adoption of these concepts by regulatory authorities is a real progress and reflects the remarkable advances in the development of drugs against molecular targets. In this respect, the oncological field provides the strongest evidence of the clinical need to link diagnostics to therapeutics. Here, we review the contribution that non-invasive nuclear imaging may give to cancer theranostics and report prominent examples of nuclear imaging procedures that can be coupled to specific therapies. The main focus lies on imaging procedures that can identify patients who will benefit from molecularly targeted therapy or are going to fail to respond to standard treatment.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(349 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote